Renaissance Technologies LLC Boosts Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Renaissance Technologies LLC raised its position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 15.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 811,488 shares of the company’s stock after acquiring an additional 106,888 shares during the period. Renaissance Technologies LLC owned approximately 1.19% of Amylyx Pharmaceuticals worth $1,542,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Amylyx Pharmaceuticals by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 5,348,139 shares of the company’s stock worth $15,189,000 after purchasing an additional 72,573 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Amylyx Pharmaceuticals by 5.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,256,861 shares of the company’s stock worth $18,501,000 after acquiring an additional 69,733 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of Amylyx Pharmaceuticals during the second quarter valued at about $2,300,000. Farallon Capital Management LLC purchased a new position in shares of Amylyx Pharmaceuticals in the 1st quarter valued at approximately $3,267,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in Amylyx Pharmaceuticals by 8.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 970,555 shares of the company’s stock worth $2,757,000 after purchasing an additional 75,775 shares in the last quarter. 95.84% of the stock is owned by hedge funds and other institutional investors.

Amylyx Pharmaceuticals Price Performance

NASDAQ:AMLX opened at $3.12 on Friday. The firm has a market capitalization of $212.18 million, a P/E ratio of -2.92 and a beta of -0.55. The company’s fifty day moving average price is $2.42 and its 200-day moving average price is $2.16. Amylyx Pharmaceuticals, Inc. has a 1-year low of $1.58 and a 1-year high of $19.95.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.35). Amylyx Pharmaceuticals had a negative net margin of 17.86% and a negative return on equity of 15.51%. The company had revenue of ($1.02) million for the quarter, compared to analysts’ expectations of $18.83 million. During the same quarter in the previous year, the business posted $0.31 EPS. Equities analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -2.27 EPS for the current fiscal year.

Analysts Set New Price Targets

AMLX has been the topic of a number of recent analyst reports. HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Amylyx Pharmaceuticals in a research note on Wednesday, July 10th. The Goldman Sachs Group raised their target price on Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the stock a “neutral” rating in a research note on Friday, July 12th. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, Amylyx Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $17.60.

Insider Activity at Amylyx Pharmaceuticals

In other news, Director George M. Milne, Jr. acquired 100,000 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were acquired at an average price of $2.20 per share, with a total value of $220,000.00. Following the purchase, the director now directly owns 858,571 shares of the company’s stock, valued at $1,888,856.20. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Amylyx Pharmaceuticals news, CEO Justin B. Klee sold 18,589 shares of the company’s stock in a transaction on Monday, September 30th. The shares were sold at an average price of $3.20, for a total transaction of $59,484.80. Following the completion of the transaction, the chief executive officer now directly owns 3,120,569 shares in the company, valued at approximately $9,985,820.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director George M. Milne, Jr. purchased 100,000 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Tuesday, September 3rd. The shares were bought at an average price of $2.20 per share, with a total value of $220,000.00. Following the transaction, the director now owns 858,571 shares in the company, valued at approximately $1,888,856.20. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 11.70% of the stock is owned by company insiders.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.